Oncolytics Biotech (ONCY) Downgraded by ValuEngine to "Hold"
Separately, Zacks Investment Research cut Oncolytics Biotech from a "hold" rating to a "sell" rating in a report on Thursday, June 7th. NASDAQ ONCY opened at $4.77 on Thursday.
from Biotech News
0 Comments